GF Xinde Life Science Investment Fund

The Bay City Capital GF Xinde International Life Sciences USD Fund, L.P. operates as a specialized investment vehicle concentrating on novel and transformative biopharmaceutical companies. This fund provides capital across all stages of development, leveraging a unique dual-market approach. Its key capabilities include identifying promising innovations in Western markets and facilitating their strategic integration with the rapidly expanding life science sector in China, thereby bridging significant geographic and industrial landscapes within healthcare investment.

This fund was formed in 2016 through a collaboration between Bay City Capital, LLC, a prominent US-based life sciences investment firm, and GF Xinde Investment Management Co., Ltd., the private equity arm wholly owned by China's GF Securities. The foundational insight behind this partnership recognized the mutual benefit of combining Bay City Capital's expertise in deal sourcing and execution in Western economies with GF Xinde's extensive strategic network and deep connections within the Chinese biotech and pharmaceutical industries, including its large client base of listed Chinese pharmaceutical companies.

The fund's primary focus is on biopharmaceutical companies located in the United States, Canada, Western Europe, and China, which benefit from its cross-border investment and strategic partnership model. Its overarching vision is to serve as a crucial portal for healthcare investment and technology licensing, providing Chinese companies with enhanced access to cutting-edge global technologies and assets, while simultaneously offering Western innovators pathways into the dynamic Chinese market, fostering mutual growth and scientific advancement.